MA49250A - Nouveaux anticorps anti-cd3 - Google Patents
Nouveaux anticorps anti-cd3Info
- Publication number
- MA49250A MA49250A MA049250A MA49250A MA49250A MA 49250 A MA49250 A MA 49250A MA 049250 A MA049250 A MA 049250A MA 49250 A MA49250 A MA 49250A MA 49250 A MA49250 A MA 49250A
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- new anti
- new
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762515293P | 2017-06-05 | 2017-06-05 | |
EP17203832 | 2017-11-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA49250A true MA49250A (fr) | 2021-04-14 |
Family
ID=62555064
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA049250A MA49250A (fr) | 2017-06-05 | 2018-06-04 | Nouveaux anticorps anti-cd3 |
Country Status (9)
Country | Link |
---|---|
US (2) | US11319371B2 (fr) |
EP (1) | EP3634998A1 (fr) |
JP (1) | JP7247110B2 (fr) |
KR (1) | KR102651965B1 (fr) |
CN (1) | CN110691789A (fr) |
AU (1) | AU2018280681A1 (fr) |
CA (1) | CA3064163A1 (fr) |
IL (1) | IL271128B1 (fr) |
MA (1) | MA49250A (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018280683A1 (en) * | 2017-06-05 | 2019-10-17 | Numab Therapeutics AG | Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA |
JP7247110B2 (ja) * | 2017-06-05 | 2023-03-28 | ヌマブ セラピューティクス アクチェンゲゼルシャフト | 新規抗cd3抗体 |
WO2023036326A1 (fr) * | 2021-09-13 | 2023-03-16 | 江苏先声药业有限公司 | Anticorps anti-cd3 humain et son utilisation |
WO2023061419A1 (fr) * | 2021-10-12 | 2023-04-20 | Concept To Medicine Biotech Co., Ltd. | Anticorps anti-cd3 avec réactivité croisée vis-à-vis des protéines humaines et de cynomolgus |
WO2023169419A1 (fr) * | 2022-03-09 | 2023-09-14 | Antengene (Hangzhou) Biologics Co., Ltd. | Nouveaux anticorps anti-cd3 et leurs utilisations |
CN115286715B (zh) * | 2022-05-18 | 2023-05-23 | 上海百英生物科技股份有限公司 | 一种抗cd3的纳米抗体或其抗原结合部分及其制备方法 |
CN116284391B (zh) * | 2022-11-16 | 2023-08-08 | 艾可泰科(浙江)控股有限公司 | 使用胰岛干细胞和抗体治疗糖尿病 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX338038B (es) | 2008-10-01 | 2016-03-30 | Amgen Res Munich Gmbh | Anticuerpo de una sola cadena bis-especifico de pscaxcd3, cd19xcd3, c-metxcd3, endosialinaxcd3, epcamxcd3, igf-1rxcd3 o fapalfaxcd3 de especies cruzadas. |
AU2012245116A1 (en) | 2011-04-20 | 2013-11-07 | Genmab A/S | Bispecific antibodies against HER2 and CD3 |
SG11201603244VA (en) | 2013-11-04 | 2016-05-30 | Glenmark Pharmaceuticals Sa | Production of t cell retargeting hetero-dimeric immunoglobulins |
JP6738285B2 (ja) | 2014-05-28 | 2020-08-12 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒト及びカニクイザルcd3イプシロンに結合する抗体 |
JP7020909B2 (ja) * | 2014-07-25 | 2022-02-16 | シトムクス セラピューティクス,インコーポレイティド | 抗-cd3抗体、活性化可能抗-cd3抗体、多重特異的抗-cd3抗体、多重特異的活性化可能抗-cd3抗体、及びそれらの使用方法 |
EP2982693A1 (fr) | 2014-08-07 | 2016-02-10 | Affimed Therapeutics AG | Domaine de liaison CD3 |
MA40894A (fr) | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
US20180244777A1 (en) | 2015-05-18 | 2018-08-30 | Numab Therapeutics AG | Novel Treatment Methods Based on Multifunctional Molecules |
JOP20160154B1 (ar) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
JP7247110B2 (ja) * | 2017-06-05 | 2023-03-28 | ヌマブ セラピューティクス アクチェンゲゼルシャフト | 新規抗cd3抗体 |
AU2018280683A1 (en) * | 2017-06-05 | 2019-10-17 | Numab Therapeutics AG | Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA |
EP3816185A1 (fr) * | 2019-11-04 | 2021-05-05 | Numab Therapeutics AG | Anticorps multi-spécifique contra pd-l1 et antigène associé à une tumeur |
EP3915580A1 (fr) * | 2020-05-29 | 2021-12-01 | Numab Therapeutics AG | Anticorps multi-spécifique |
US20230203162A1 (en) * | 2020-05-29 | 2023-06-29 | Numab Therapeutics AG | Multispecific antibody |
-
2018
- 2018-06-04 JP JP2019566606A patent/JP7247110B2/ja active Active
- 2018-06-04 AU AU2018280681A patent/AU2018280681A1/en active Pending
- 2018-06-04 US US16/619,121 patent/US11319371B2/en active Active
- 2018-06-04 EP EP18729644.7A patent/EP3634998A1/fr active Pending
- 2018-06-04 KR KR1020197035542A patent/KR102651965B1/ko active IP Right Grant
- 2018-06-04 CN CN201880036701.7A patent/CN110691789A/zh active Pending
- 2018-06-04 MA MA049250A patent/MA49250A/fr unknown
- 2018-06-04 IL IL271128A patent/IL271128B1/en unknown
- 2018-06-04 CA CA3064163A patent/CA3064163A1/fr active Pending
-
2022
- 2022-04-22 US US17/727,449 patent/US20220403028A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11319371B2 (en) | 2022-05-03 |
IL271128B1 (en) | 2024-06-01 |
CN110691789A (zh) | 2020-01-14 |
KR20200013233A (ko) | 2020-02-06 |
US20200115449A1 (en) | 2020-04-16 |
CA3064163A1 (fr) | 2018-12-13 |
IL271128A (en) | 2020-01-30 |
KR102651965B1 (ko) | 2024-03-28 |
US20220403028A1 (en) | 2022-12-22 |
EP3634998A1 (fr) | 2020-04-15 |
AU2018280681A1 (en) | 2019-12-05 |
JP2020522260A (ja) | 2020-07-30 |
JP7247110B2 (ja) | 2023-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA47694A (fr) | Anticorps anti-tigit | |
MA49034A (fr) | Anticorps anti-lag3 | |
MA52742A (fr) | Anticorps bispécifiques dll3-cd3 | |
FR21C1030I2 (fr) | Conjugué anticorps anti-her2-médicament | |
DK3625259T3 (da) | Anti-sirpalpha-antistoffer | |
MA53434A (fr) | Anticorps anti-tigit | |
MA47268A (fr) | Anticorps anti-gpc3 | |
MA52884A (fr) | Anticorps anti-il-11 | |
MA42626A (fr) | Nouveaux anticorps anti-pd-1 | |
MA46525A (fr) | Anticorps anti-lag-3 et compositions | |
MA50505A (fr) | Anticorps 2 + 1 bispécifiques (contorsbodies) | |
KR102162129B9 (ko) | 항-갈렉틴-9 항체 및 이의 용도 | |
MA45004A (fr) | Anticorps spécifiques anti-wt1-hla | |
DK3515487T3 (da) | Bispecifikke anti-MUC16-CD3-antistoffer og anti-MUC16-lægemiddelkonjugater | |
MA44659A (fr) | Anticorps anti-tim-3 et compositions | |
MA46057A (fr) | Anticorps anti-ctla4 | |
KR102355950B9 (ko) | Tigit에 대한 항체 | |
MA53297A (fr) | Anticorps anti-icos | |
MA50352A (fr) | Anticorps multispécifiques | |
DK3504241T3 (da) | Anti-cd3-antistofformuleringer | |
MA47472A (fr) | Anticorps | |
DK3606961T3 (da) | Garp-tgf-beta-antistoffer | |
MA49749A (fr) | Anticorps anti-cd137 | |
MA49250A (fr) | Nouveaux anticorps anti-cd3 | |
MA52366A (fr) | Anticorps anti-tl1a optimisés |